Covaxin has been granted emergency use authorization in 13 countries, government informs parliament
The central government informed Parliament on Friday that Bharat Biotech’s Covaxin had obtained Emergency Use List (EUL) in 13 countries as of January 31 according to the WHO.
Covaxin Stock Photo | PTI
Covaxin has been granted Emergency Use List (EUL) in 13 countries as of January 31 according to the WHO, Minister of State for Health Bharati Pravin Pawar informed the Lok Sabha on Friday.
Responding to a question, she said that Covaxin obtained the EUL from the national regulator, Drugs Controller General of India (DCGI), in the age group of 12 to 18 on December 24, 2021.
NTAGI’s COVID-19 task force recommended Covid vaccination for adolescents aged 15 to 18, Pawar said in a written response.
READ: Indian scientists create new self-disinfecting, biodegradable Covid masks
On the recommendation of the COVID-19 Task Force and the Standing Technical Sub-Committee of the National Technical Advisory Group on Immunization (NTAGI), the Government of India has started vaccination of adolescents aged 15-18 from January 3.
“Approval of a vaccine by any country is a technical and scientific process for which data must be submitted to the regulatory body by the vaccine manufacturer in accordance with prescribed rules. According to the WHO, at 31 January 2022, Covaxin has been granted EUL in 13 countries,” she said.
As to whether the government has noted the difficulties faced by foreign companies in sourcing Covaxin from Bharat Biotech, Pawar said that no specific information has been made known by foreign companies that they are encountering difficulties. difficulties in vaccine supply.
During the second outbreak of the pandemic in the country in April and May last year, the requirements of the national COVID-19 vaccination program took priority. This may have impacted foreign commercial contracts entered into by domestic vaccine makers, she said.
On whether the government has assessed the probable financial loss due to this, Pawar said that as advised by the Ministry of External Affairs, there is no financial loss involved since in the second wave, the national vaccine production was purchased and used in the National COVID-19. Immunization program.
Click here for IndiaToday.in’s full coverage of the coronavirus pandemic.